New at CADTH — March 2022

( Last Updated : March 4, 2022)
Project Line:
New at CADTH


Corporate News and Events

CADTH Information Session

CADTH is pleased to invite you to its annual Information Session, where we will be sharing the latest plans for our drug and health technology portfolios and introducing our 2022–2025 strategic plan.

  • Date: Tuesday, April 5, 2022
  • Time: 11:00 a.m. to 3:30 p.m. EST

The CADTH Strategic Plan serves as a foundational document for the organization, guiding our evolution, and shaping our long-term ambition to anticipate and enable future-ready health care. Join us to learn what themes we heard from stakeholders across the country and how we conceived a plan to guide CADTH to the forefront of health technology management in Canada.


  • Remarks from David Agnew, Chair, CADTH Board of Directors
  • Remarks from Dr. Stephen Lucas, Deputy Minister, Health Canada
  • Presentations from CADTH’s executive leadership team
  • Question and answer opportunities

Subscribe to CADTH E-Alerts to be notified when registration for the CADTH Information Session opens.

CADTH Post-Market Drug Evaluation Program

CADTH launched its Post-Market Drug Evaluation Program on February 4. This new program extends our expertise in pharmaceutical management, and will involve building and coordinating a network that leverages Canadian expertise in applied drug research, methodology, and data analysis.

CADTH Expert and Advisory Committees Call for Nominations

Our experts need your expertise. CADTH is seeking nominations to our expert and advisory committees. We’re looking for 14 individuals with significant expertise in the Canadian health care system to join various committees. More information about the roles, the nomination process, honorarium, and time commitments will be available starting on March 14, 2022.

CADTH 2022 Health Technology Trends to Watch

Join CADTH on March 17 for the launch of the 2022 Health Technology Trends to Watch report. CADTH’s annual report offers insight into the health technologies that are likely to disrupt the delivery of health care in Canada over the next 2 to 3 years. Registration is required.

CADTH Reports and Recommendations

Reimbursement Reviews

Drug funding recommendations for Canada's federal, provincial, and territorial public drug programs. Reimbursement recommendations are based on comprehensive assessments of the clinical and pharmacoeconomic evidence, and input from pharmaceutical companies, clinicians, and patient groups.


CADTH Horizon Scans

Information about new and emerging health technologies that could impact the delivery of care in Canada


CADTH Health Technology Reviews

Independent assessments of health technologies. Assessments consist of one, or a combination, of the following: an environmental scan, a rapid review, a clinical (or systematic) review, an economic review, and a review of patient perspectives. They may also include an assessment of the legal, ethical, social, implementation, environmental, and policy implications of the health technology. Recommendations on the appropriate use of health technologies are provided where applicable:


CADTH Reference Lists

Lists of the publicly available and grey literature, that identify the available evidence and the gaps in the scientific literature.


Tell Us What You Think


We love hearing how our products and services are influencing health care policies, clinical practices, and patient outcomes. If you have a success story to share, please get in touch with your CADTH Liaison Officer.

CADTH E-Alerts: Subscribe to receive the latest CADTH news, reports, feedback opportunities, and events.